• Title: Alseres Pharmaceuticals Hosts 2007 Financial Results Conference Call
• Artist: Zangani Investor Community(TM)
• Length: 34:36 minutes (7.92 MB)
• Format: Mono 22kHz 32Kbps (CBR)

Today Alseres Pharmaceuticals, Inc. hosted a conference call to reviewing the 2007 financial results and discuss other matters related to the Company.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. Our lead product candidate is ALTROPANE® which is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.